Eli Lilly's stock has surged by 562.65% since 2020, reflecting a 700% growth in market capitalization, indicating strong investor confidence and positive prospects.
J.P. Morgan forecasts Eli Lilly’s Q3 sales at $11.8 billion, propelled by robust U.S. GLP-1 sales and international expansion of Mounjaro, despite slight underperformance against consensus.
The upcoming earnings report is crucial for Eli Lilly, with expectations for a 4,430% increase in earnings per share compared to last year, showcasing potential growth.
Concerns have emerged regarding Eli Lilly's Alzheimer's drug, donanemab, after it was linked to patient deaths during trials, raising questions about its safety and efficacy.
Collection
[
|
...
]